Journal Information
Vol. 44. Issue S1.
Pages S24 (October 2022)
Share
Share
Download PDF
More article options
Vol. 44. Issue S1.
Pages S24 (October 2022)
SUPPORTIVE CARE AND PALLIATIVE CAREOP 22
Open Access
IMPACT OF COVID-19 PANDEMIC ON DELAY OF CHILDHOOD CANCER DIAGNOSIS AND THE OUTCOMES IN A PEDIATRIC HEMATOLOGY/ONCOLOGY DEPARTMENT
Visits
527
Selma CAKMAKCI1, Neriman SARI1, Arzu YAZAL ERDEM1, Sonay INCESOY OZDEMIR1, Derya OZYORUK1, Aslınur OZKAYA PARLAKAY1, İnci ERGURHAN ILHAN1
1 Ankara City Hospital
This item has received

Under a Creative Commons license
Article information
Special issue
This article is part of special issue:
Vol. 44. Issue S1
More info
Objective

Restriction of access to healthcare during COVID-19 pandemic is undoubtedly a major problem for patients with cancer. Although childhood cancers are highly curable, it is obvious that diagnostic and treatment disruptions will lead to poor Results. In this study we investigated the effects of pandemic on diagnosis and treatment delays of children with cancer along with their consequences.

Methodology

We searched all pediatric patients treated for cancer between March 2020 and January 2022 for COVID-19 infection. Data were collected collected from medical files of patients diagnosed with COVID-19, confirmed by polymerase chain reaction (PCR), who received active antineoplastic treatment.

Results

Fifty-eight patients developed COVID-19 infection at different stages of their anticancer treatment. Twenty-five had an asymptomatic COVID-19 infection, twenty-six had mild symptoms, three had moderate symptoms and four had severe disease. All of them recovered from COVID-19 infection. Chemotherapy courses were continued during active infection in four patients and interrupted in other patients.

Conclusion

While strict measures are required to control the pandemic, patients with severe critical illness such as cancer should be carefully evaluated and treatment delays that may have vital consequences should be avoided. In pediatric patients with cancer whom infected by COVID-19, continuation of anticancer treatment may be considered by evaluating the clinical status of the patient.

Full text is only aviable in PDF
Idiomas
Hematology, Transfusion and Cell Therapy
Article options
Tools